The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry.
The largest deal of the week is a global development and commercialization agreement for DS-1062 between AstraZeneca plc and Daiichi Sankyo Company valued at $1 billion. DS-1062 is Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), and potential new medicine for the treatment of multiple tumor types. The companies will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. AstraZeneca and Daiichi Sankyo will share equally development and commercialization expenses as well as profits relating to DS-1062 worldwide, except for Japan.
To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to developments in all the key segments of the health care service and technology markets.
Click here to view our quarterly and annual publications and here to view our monthly webinar series.
| Behavioral Health Care | ||
| Acquirer | Target | Price |
| WindRose Health Investors, LLC | Caregiver Inc. | N/A |
| Biotechnology | ||
| Acquirer | Target | Price |
| AstraZeneca plc | DS-1062 development and commercialization agreement | $1,000,000,000 |
| Atsena Therapeutics | Rights to Gene Therapy for GUCY2D | N/A |
| Arya Sciences Acquisition Corp II | Cerevel Therapeutics, Inc. | N/A |
| Genentech, Inc. | License to UCB0107 | $120,000,000 |
| eHealth | ||
| Acquirer | Target | Price |
| Ciox Health | Medal, Inc. | N/A |
| Sharecare, Inc. | WhiteHatAI | N/A |
| TA Associates & Francisco Partners | Edifecs, Inc. | N/A |
| Healthcare Merger Corp. | Specialists On Call, Inc. | $720,000,000 |
| Strata Decision Technology | EPSi | $365,000,000 |
| Laboratories, MRI and Dialysis | ||
| Acquirer | Target | Price |
| Recursion | Vium | N/A |
| Long-Term Care | ||
| Acquirer | Target | Price |
| Local buyer | Chelsea of Jenkintown | $3,000,000 |
| Pharmaceuticals | ||
| Acquirer | Target | Price |
| Stanley Capital | Noden | $45,000,000 |
| Physician Medical Groups | ||
| Acquirer | Target | Price |
| MB2 Dental Solutions | Lake Erie Dental | N/A |
| Other Services | ||
| Acquirer | Target | Price |
| LGM Pharma | Nexgen Pharama CDMO business | N/A |
| Methodist Healthcare System | 5 freestanding emergency centers | N/A |
| Stage Equity Partners | 2 MOBs in Texas | N/A |
| IRA Capital | Paramount Surgery Center | $7,000,000 |
